Arg1190

Site Information
QGYrGrGrGEyYSrG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12191661
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:	lung cancer ( 3 , 4 ) , non-small cell lung cancer ( 3 , 5 , 6 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 6 ) , non-small cell squamous cell lung carcinoma ( 4 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 ) , A549 (pulmonary) ( 3 ) , HCC15 (pulmonary) ( 4 ) , HCT116 (intestinal) ( 2 , 7 , 8 , 9 ) , LOU-NH91 (squamous) ( 4 ) , lung ( 3 , 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1703 (squamous) ( 4 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H2073 (pulmonary) ( 4 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 3 )

References
1	Larsen SC, et al. (2016) Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci Signal 9, rs9 27577262 Curated Info
2	Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87 24129315 Curated Info
3	Rikova K (2013) CST Curation Set: 20096; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
4	Rikova K (2013) CST Curation Set: 20099; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
5	Rikova K (2013) CST Curation Set: 18851; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
6	Rikova K (2013) CST Curation Set: 18850; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015 Curated Info
7	Mulhern D (2011) CST Curation Set: 13243; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (R*GG) (D5A12) Rabbit mAb Cat#: 8711, PTMScan(R) Mono-Methyl Arginine (D5A12) Immunoaffinity Beads Cat#: 8963 Curated Info
8	Zhou J (2008) CST Curation Set: 5632; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
9	Zhou J (2008) CST Curation Set: 5148; Year: 2008; Biosample/Treatment: cell line, HCT116/Adox; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info